Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inhibrx BiosciencesINBX +6.47%6 PS Ratio is 1,174.64 as of Aug. 13, 2026, which is 33% above its 10-year median of 882.41. GuruFocus rates INBX with a GF Score™ of 6/100. The stock has 5 warning signs investors should review. Among 930 Biotechnology companies, Inhibrx Biosciences ranks worse than 96.67% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Inhibrx Biosciences's share price is $98.67.
Inhibrx Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.08. Hence, Inhibrx Biosciences's PS Ratio for today is 1,174.64.
The historical rank and industry rank for Inhibrx Biosciences's PS Ratio or its related term are showing as below:
INBX'
s PS Ratio Range Over the Past 10 Years
Min: 84.92 Med: 882.41 Max: 1599.4
Current: 1170.97
During the past 4 years, Inhibrx Biosciences's highest PS Ratio was 1599.40. The lowest was 84.92. And the median was 882.41.
INBX's PS Ratio is ranked worse than 96.67% of 930
companies
in the Biotechnology industry
Industry Median: 9.6
vs INBX: 1170.97
During the past 4 years, Inhibrx Biosciences's highest 3-Year average Revenue per Share Growth Rate was -2.60% per year. The lowest was -2.60% per year. And the median was -2.60% per year.
Inhibrx Biosciences (NAS:INBX) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Inhibrx Biosciences PS Ratio Related Terms
Inhibrx Biosciences PS Ratio Historical Data
* Premium members only.
The historical data trend for Inhibrx Biosciences's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Inhibrx Biosciences's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inhibrx Biosciences PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inhibrx Biosciences's PS Ratio distribution charts can be found below:
* The bar in red indicates where Inhibrx Biosciences's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Inhibrx Biosciences's Share Price of today is $98.67. Inhibrx Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.08.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Inhibrx Biosciences (INBX) has a PS Ratio of 1,174.64 as of Aug. 13, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Inhibrx Biosciences and its competitors. This is 33% above median its historical median of 882.41. Over the past decade, Inhibrx Biosciences' PS Ratio has ranged from 84.92 to 1,599.40. According to the industry distribution chart, Inhibrx Biosciences ranks #899 out of 930 companies in the Biotechnology industry, placing it in the top 96.7%.
Is Inhibrx Biosciences' PS Ratio too high?
Inhibrx Biosciences' current PS Ratio of 1,174.64 is 33% above median its 10-year median of 882.41. Over the past 10 years, this metric has ranged from a low of 84.92 to a high of 1,599.40. The Biotechnology industry median PS Ratio is 9.60. Inhibrx Biosciences' value of 1,174.64 is 12135.8% above this industry median. Based on the distribution chart, Inhibrx Biosciences ranks #899 out of 930 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Inhibrx Biosciences has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Inhibrx Biosciences' PS Ratio compare to JBIO and NVAX?
According to the Biotechnology industry distribution chart, Inhibrx Biosciences ranks #899 out of 930 companies for PS Ratio. This places Inhibrx Biosciences in the lower half of its industry. The industry median PS Ratio is 9.60. Inhibrx Biosciences' value of 1,174.64 is 12135.8% above this benchmark. Historically, Inhibrx Biosciences' own PS Ratio has ranged from 84.92 to 1,599.40 over the past decade. While the company's 10-year median is 882.41 vs. the industry median of 9.60, Inhibrx Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.60, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inhibrx Biosciences's current PS Ratio of 1,174.64 is 12135.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Inhibrx Biosciences and its competitors. For the Biotechnology industry, the median PS Ratio is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inhibrx Biosciences's current PS Ratio is 1,174.64, which is 33% above median its own 10-year median of 882.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhibrx Biosciences stock overvalued right now?
Inhibrx Biosciences (INBX) has a current PS Ratio of 1,174.64. The current PS Ratio is 1,174.64, which is 33% above median its 10-year median of 882.41 and 12135.8% above the Biotechnology industry median of 9.60. Inhibrx Biosciences' overall GF Score™ is 6/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Inhibrx Biosciences (INBX), the current PS Ratio is 1,174.64 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
6GF Score
Get the complete analysis for INBX
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INBX has been successfully added to your 
